LETTER TO THE EDITOR
Enhancing hepatitis C management in ESRD: Evaluating efficacy and safety of alternative antiviral regimens
Ume Aiman,
Corresponding Author
Ume Aiman
Islamic International Medical College, Rawalpindi, Pakistan
Correspondence
Ume Aiman, Islamic International Medical College, Peshawar Road, Rawalpindi, 44000, Pakistan.
Email: [email protected]
Search for more papers by this author Umer Bin Shahzad,
Umer Bin Shahzad
Islamic International Medical College, Rawalpindi, Pakistan
Search for more papers by this author
Ume Aiman,
Corresponding Author
Ume Aiman
Islamic International Medical College, Rawalpindi, Pakistan
Correspondence
Ume Aiman, Islamic International Medical College, Peshawar Road, Rawalpindi, 44000, Pakistan.
Email: [email protected]
Search for more papers by this author Umer Bin Shahzad,
Umer Bin Shahzad
Islamic International Medical College, Rawalpindi, Pakistan
Search for more papers by this author
First published: 14 September 2024
No abstract is available for this article.
REFERENCES
- 1Toyoda H, Kikuchi K. Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy. Ther Apher Dial. 2023; 27(5): 831–838. https://doi.org/10.1111/1744-9987.14003
- 2Taneja S, Duseja A, Mehta M, de A, Verma N, Premkumar M, et al. Sofosbuvir and velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis. Liver Int. 2021; 41(4): 705–709. https://doi.org/10.1111/LIV.14685
- 3 FDA. SOVALDI® (sofosbuvir) tablets, for oral use [cited 9 Aug 2024]. Available from: http://www.fda.gov/medwatch
- 4Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019; 71(4): 660–665. https://doi.org/10.1016/j.jhep.2019.05.028
- 5Roth D, Nelson DR, Bruchfeld A, Liapakis AM, Silva M, Monsour H Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015; 386(10003): 1537–1545. https://doi.org/10.1016/S0140-6736(15)00349-9
- 6Hsu PY, Wei YJ, Lee JJ, Niu SW, Huang JC, Hsu CT, et al. Comedications and potential drug–drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. Clin Mol Hepatol. 2020; 27(1): 186–196. https://doi.org/10.3350/cmh.2020.0180
- 7 Patients with renal impairment. HCV Guidance [cited 9 Aug 2024]. Available from: https://www.hcvguidelines.org/unique-populations/renal-impairment
